Abbvie Inc.

Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target

If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population

Sales of top brands from both Lilly and Novo recorded all-time highs, again

BioCentury’s editors also discuss recommendations for early stage rare disease drug development

Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more

Does the deal signal additional support for amylin monotherapy, or suggest the pharma may soon make deals for complementary mechanisms?

Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing

Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more

Plus: Olazábal leaving Ysios and updates from Augustine and Prolific